Trials / Completed
CompletedNCT01215526
A Study Into the Effectivity and Safety of Firmagon, Prescribed for Treatment of Patients With Advanced Prostate Cancer
Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in the Netherlands
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 274 (actual)
- Sponsor
- Ferring Pharmaceuticals · Industry
- Sex
- Male
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Patients eligible for hormone ablation therapy who are prescribed Firmagon will be followed for a maximum of 3 years to estimate the progression free survival. Data on testosteron levels, QoL and LUTS will be collected if this information is available. Safety information (adverse events) will be collected.
Conditions
Timeline
- Start date
- 2010-10-01
- Primary completion
- 2015-07-01
- Completion
- 2015-07-01
- First posted
- 2010-10-06
- Last updated
- 2015-08-19
Locations
47 sites across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT01215526. Inclusion in this directory is not an endorsement.